Sanofi (SNY) entered a merger agreement on June 2, 2025, to acquire Blueprint Medicines Corporation (BPMC) in a deal valued at $9.1 billion.
Under the terms of the agreement, Sanofi will commence a cash tender offer to acquire all outstanding shares of Blueprint for $129 per share in cash, representing a 27.28% premium on the stock’s last close.
In addition, Blueprint’s shareholders will receive one non-tradeable CVR per Blueprint share with two potential milestone payments: $2 per share, conditioned upon the achievement of a clinical development milestone for BLU-808, and $4 per share, conditioned upon the achievement of a regulatory milestone for BLU-808.
Blueprint Medicines is a global biopharmaceutical company focused on developing precision therapies for genomically defined cancers, blood disorders, and mast cell diseases. The company leverages deep scientific expertise to advance a broad pipeline and has two approved medicines, including Ayvakit for systemic mastocytosis.
Sanofi is a global, R&D-driven biopharmaceutical company that develops medicines and vaccines across immunology, oncology, rare diseases, and consumer healthcare.
The deal includes a drug for systemic mastocytosis, a rare immunological disorder, approved in both the U.S. and the European Union under the brand names Ayvakit and Ayvakyt, as well as an early-stage immunology pipeline.
Sanofi intends to fund the transaction, expected to close in the third quarter of 2025, using a mix of cash on hand and newly raised debt.
Sanofi is acquiring Blueprint Medicines at 14.43 times its sales.
For more details regarding this merger and acquisition transaction, please visit the Deal Metrics page:
Deal Metrics for the acquisition of Blueprint Medicines Corporation (BPMC) by Sanofi (SNY)
The Deal Metrics page provides a wealth of information regarding each merger or acquisition, including a spread history chart, a timeline of important events, news and SEC filings, deal updates, and more.
Disclaimer: The information provided in this article is intended for informational purposes only and should not be considered as investment advice. We recommend conducting thorough research and/or consulting a professional before making any investment decisions. The accuracy and completeness of the data provided in this article are not guaranteed.
Editor’s Note: Baranjot Kaur contributed to this article